The Swiss pharmaceutical giant Novartis announced a major overhaul of its operations on Tuesday, marked by an agreement to buy the cancer drug
business of its British rival GlaxoSmithKline for up to $16 billion. The deals come amid a flurry of eye-popping transactions in the drug sector in recent months and speculation about even more to
come.
Read the whole story at The New York Times »